Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal


Suchbegriffe: ABCSG 8, . Treffer: 3


Singer, CF; Jahn, SW; Rudas, M; Bago-Horvath, Z; Fitzal, F; Abete, L; Moinfar, F; Gnant, M; Filipits, M, , Austrian, Breast, and, Colorectal, Cancer, Study, Group, (ABCSG) Independent validation of stromal uPA in ABCSG-08: Level 1b evidence for the prognostic value of uPA immunohistochemistry.
Breast. 2022; 64:127-133 Doi: 10.1016/j.breast.2022.05.003 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG



Fitzal, F; Filipits, M; Rudas, M; Greil, R; Dietze, O; Samonigg, H; Lax, S; Herz, W; Dubsky, P; Bartsch, R; Kronenwett, R; Gnant, M The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial.
Br J Cancer. 2015; 112(8):1405-1410 Doi: 10.1038/bjc.2015.98 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG



Gnant, M; Filipits, M; Greil, R; Stoeger, H; Rudas, M; Bago-Horvath, Z; Mlineritsch, B; Kwasny, W; Knauer, M; Singer, C; Jakesz, R; Dubsky, P; Fitzal, F; Bartsch, R; Steger, G; Balic, M; Ressler, S; Cowens, JW; Storhoff, J; Ferree, S; Schaper, C; Liu, S; Fesl, C; Nielsen, TO; Austrian Breast and Colorectal Cancer Study Group Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
Ann Oncol. 2014; 25(2):339-345 Doi: 10.1093/annonc/mdt494 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG


© Med Uni Graz Impressum